Tucson / Indianapolis / Jersey City / Bristol / Marina del Rey / /
Company
Pfizer / New Concepts Identified Per Domain Group / Sunovion Pharmaceuticals / Eli Lilly and Company / 3Health Research Associates / 2Abbott Laboratories / MEDLINE / PRO Consortium Depression Working Group / Lilly / PROMIS Depression Item Bank / Forest Laboratories / Abbott Laboratories / Janssen / Myers Squibb / Depression Working Group / Shire / /
Country
United States / /
Currency
SRG / /
Event
FDA Phase / /
Facility
Hospital Anxiety / Path Institute / Institute of Scientific Information / Some College / PRO Consortium Depression Working Group 1Forest Research Institute / University of Oxford PRO Measurement Group / Critical Path Institute / Cochrane Library / /
IndustryTerm
secondary search / Online Guide / drug development tools / internet sources / focus / /
MedicalCondition
major depressive disorder / Disease / Cognitive Symptoms / target disease / OUTCOME (PRO) MEASURE FOR MAJOR DEPRESSIVE DISORDER / Depression / /
Organization
U.S. Department of Health and Human Services / High School / Institute of Scientific Information / 5Critical Path Institute / International Society for CNS Clinical Trials / Some College / Professional School / U.S. Food and Drug Administration / Center for Epidemiologic Studies / Critical Path Institute / Center for Drug Evaluation and Research / University of Oxford PRO Measurement Group / PRO Consortium Depression Working Group 1Forest Research Institute / International Society for Pharmacoeconomics and Outcomes Research / United States Food and Drug Administration / /
DEVELOPMENT OF A NEW PATIENT‐REPORTED OUTCOME (PRO) MEASURE FOR MAJOR DEPRESSIVE DISORDER: RESULTS OF A CONSORTIUM‐BASED APPROACH Blum, SI1; Greco, N2; Martin, ML3; Hayes, RP4; Coons, SJ5 on